|
Cambridge (I-Newswire) March 8, 2011 - CAMBRIDGE, MA - Semprus BioSciences today announced the election of its Chief Executive Officer David L. Lucchino to the Advanced Medical Technology Association (AdvaMed) Board of Directors. AdvaMed, based in Washington, D.C., is the world's largest trade association representing approximately 400 of the world's leading medical device and diagnostics manufacturers.
AdvaMed advocates for a legal, regulatory and economic environment that advances global health care by assuring worldwide patient access to the benefits of medical technology. The Association promotes policies that foster the highest ethical standards, rapid product approvals, appropriate reimbursement, and international market access - and is committed to giving emerging growth companies an active voice among the world's leading medical technology firms. These companies, most with less than 100 employees, are in the highly competitive business of creating constant progress through constant innovation, according to AdvaMed, and generate 28% of the industry's R&D spending.
In his role as Board member, Mr. Lucchino will serve on AdvaMed's International Policy Committee, where he will contribute to its mission of improving market access and promoting the value of medical technology, especially in Japan, Germany, France and the UK. He is also a member of the Emerging Company Issues subcommittee of AdvaMed's 2011 Medtech Conference in September.
"We are pleased to have David join the Board. His knowledge and experience will help us promote pro-growth policy solutions that advance innovation and patient care in the U.S. and around the world," said Stephen J. Ubl, President and CEO of AdvaMed. "We are particularly pleased to have another voice for emerging growth companies on the Board."
"Innovating solutions to address substantial unmet medical needs is something that emerging growth firms do particularly well," said Mr. Lucchino. "AdvaMed fulfills a critical leadership role as an innovation champion for companies of all sizes, and I'm thankful for the opportunity to be part of the team at the forefront of the association's operations."
1 Journal of Wound Care, February 2010 (Wilcott et al.), Chronic Wounds and the Medical Biofilm Paradigm.
About Semprus BioSciences
Semprus BioSciences is a venture-funded biomedical company designing new tools for clinicians and patients to reduce the 56,000 annual U.S. deaths and more than $11 billion cost of infection- and thrombus-related complications1 that arise when vascular access products are implanted in the body. These products are components of the Semprus Platform, a single-surface modification designed to reduce the attachment of bacteria, fungus, platelets and blood proteins to an implanted medical device. The company spun out of the labs of biomedical researcher and Massachusetts Institute of Technology (MIT) Professor Robert Langer, Sc.D., in 2007.
In December 2010, the company completed an $18 million Series B financing co-led by SR One, the corporate venture capital arm of GlaxoSmithKline, and Foundation Medical Partners (FMP), a national healthcare venture capital investment firm with a strategic relationship with Cleveland Clinic. Combined with previous financing rounds, Semprus has raised a total of $28.5 million in equity.
Visit http://www.semprusbio.com for additional information.
Semprus BioSciences won Frost & Sullivan's "2010 North American Enabling Technology of the Year Award for Surface in Functionalization Technologies" for its Semprus Platform in December 2010.
Semprus BioSciences was selected as one of "50 Companies to Watch" by Medical Devices & Diagnostics Industry magazine in June 2010.
About Semprus BioSciences:
Semprus BioSciences, headquartered in Cambridge, Massachusetts, is a venture-backed biomedical company with a dual mission: to provide complication-free medical devices designed to preserve patients’ long-term health and quality-of-life and to contribute to health care cost efficiencies. Our innovative, multi-faceted approach to durable surface modifications signifies a breakthrough in medical device technology. Our current focus is to enable the first permanently dual-functional (anti-colonization and anti-thrombogenic) vascular access catheter with a single surface modification.
Founded out of the Massachusetts Institute of Technology's Langer Lab, the company has developed the next-generation biofunctional surface platform – which is focused on achieving clinical benefits that far exceed current market offerings containing silver, heparin, and antibiotic coatings. Through covalent chemical bonding of our Semprus Surfaces™, a permanent non-leaching biomaterial modification to the device surface, our technology is expected to vastly improve patient outcomes by preventing serious medical complications, such as infection, blood clots, improper healing, and cell overgrowth. We have assembled a world class product development team – scientists, industry executives and clinical experts – who specialize in reducing such complications at the confluence of the human body and implantable devices.
In December 2010, Semprus BioSciences completed an $18 million Series B financing round co-led by SR One, the corporate venture capital arm of GlaxoSmithKline, and Foundation Medical Partners (FMP), a national healthcare venture capital investment firm with a strategic relationship with Cleveland Clinic. Prior to this, Semprus completed a Series A financing round co-led by a venture capital firm focused on building next-generation life science companies, and Pangaea Ventures, a venture capital firm that invests in advanced materials, energy, biomedical, and environmental technology companies, in December 2008. This funding came on the heels of our $2.5 million seed capital raised in 2007.
Additionally, we have worldwide licenses secured from MIT and the University of Washington, and hold numerous proprietary intellectual property filings. Our laboratory and office complex is located in Kendall Square, Cambridge's innovative biomedical center, and employs 27 full-time professionals.
Company Contact Information
Semprus BioSciences
Michael Devine
One Kendall Square
Building 1400W, 1st Floor
02139
Phone : 6175777755
|
